In vitro antimicrobial resistance in clinical isolates of bacterial pathogens causing bovine respiratory disease: a systematic review and meta-analysis
- 1University of Copenhagen
Abstract
Background: Bovine respiratory disease (BRD) is a major cause of antimicrobial use in cattle, raising concerns about antimicrobial resistance (AMR). This systematic review estimated pooled AMR proportions in BRD pathogens: Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni, and assessed temporal and geographic trends in resistance. Methods: Five antimicrobials commonly used for BRD treatment were evaluated: penicillin G (PEN), tetracycline (TET), florfenicol (FLO), tulathromycin (TUL), and enrofloxacin (ENR). Following PRISMA guidelines, 1,097 records were screened and 24 studies met inclusion criteria. Study quality and risk of bias were assessed, and random-effects meta-analyses estimated pooled proportions of resistant isolates by antimicrobial, continent and period. Results: A total of 13,949 bacterial isolates were analysed including P. multocida (5,615), M. haemolytica (5,585), and H. somni (2,749). TET resistance was highest across all pathogens (12-30%), followed by TUL (6-11%), PEN (4-12%), FLO (0.5-1.6%) and ENR (0.2-1.1%). TET resistance in M. haemolytica and P. multocida, and FLO resistance in P. multocida were significantly more frequent in North America than in Europe (p[≤]0.05). TUL resistance increased significantly in P. multocida after 2013 (p=0.038), with similar non significant trends in M. haemolytica and H. somni. FLO resistance decreased significantly in H. somni after 2013 (p=0.013). Egger's test identified significant funnel plot asymmetry for ENR resistance in H. somni and PEN resistance in M. haemolytica, suggesting possible small study effects. Conclusion: These results offer insights into distribution of phenotypic resistance across pathogens and regions, informing BRD antimicrobial treatment guidelines and One-Health antimicrobial stewardship aimed at preserving the effectiveness of medically important antimicrobials.
Related
- Editorial: Evolution of antimicrobial resistance in intracellular bacterial pathogens: a genomic and historical perspective
- Whole-Genome Sequencing Unravels Virulence and Antimicrobial Resistance Landscapes of Major Bovine Respiratory Disease Pathogens.
- WHO Bacterial Priority Pathogens List: a 32-year global trend and inequality analysis of antimicrobial resistance burden by age and region.
- Global landscape of community carriage of antimicrobial resistant bacterial pathogens: protocol for a systematic review and meta-analysis
- LysM: a bacterial self-encoded peptidoglycan hydrolase as an antimicrobial and anti-biofilm agent for Gram-negative nosocomial pathogens
BibTeX
@misc{mahmood2026vitro,
title = {{In vitro antimicrobial resistance in clinical isolates of bacterial pathogens causing bovine respiratory disease: a systematic review and meta-analysis}},
author = {Q. Mahmood and P. Rasmussen and P. P. Damborg and K. B. Hansen and C. B. Gregersen and K. A. Scahill and L. P. Carmo and C. L. Firth and B. Pardon and M. Stokstad and L. M. Anestad and L. Guardabassi and B. Conrady},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.28.754992},
url = {https://www.biorxiv.org/content/10.64898/2026.09.28.754992v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - In vitro antimicrobial resistance in clinical isolates of bacterial pathogens causing bovine respiratory disease: a systematic review and meta-analysis
AU - Q. Mahmood
AU - P. Rasmussen
AU - P. P. Damborg
AU - K. B. Hansen
AU - C. B. Gregersen
AU - K. A. Scahill
AU - L. P. Carmo
AU - C. L. Firth
AU - B. Pardon
AU - M. Stokstad
AU - L. M. Anestad
AU - L. Guardabassi
AU - B. Conrady
PY - 2026
DA - 2026/09/28
PB - bioRxiv
DO - 10.64898/2026.09.28.754992
UR - https://www.biorxiv.org/content/10.64898/2026.09.28.754992v1
AB - Background: Bovine respiratory disease (BRD) is a major cause of antimicrobial use in cattle, raising concerns about antimicrobial resistance (AMR). This systematic review estimated pooled AMR proportions in BRD pathogens: Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni, and assessed temporal and geographic trends in resistance. Methods: Five antimicrobials commonly used for BRD treatment were evaluated: penicillin G (PEN), tetracycline (TET), florfenicol (FLO), tulathromycin (TUL), and enrofloxacin (ENR). Following PRISMA guidelines, 1,097 records were screened and 24 studies met inclusion criteria. Study quality and risk of bias were assessed, and random-effects meta-analyses estimated pooled proportions of resistant isolates by antimicrobial, continent and period. Results: A total of 13,949 bacterial isolates were analysed including P. multocida (5,615), M. haemolytica (5,585), and H. somni (2,749). TET resistance was highest across all pathogens (12-30%), followed by TUL (6-11%), PEN (4-12%), FLO (0.5-1.6%) and ENR (0.2-1.1%). TET resistance in M. haemolytica and P. multocida, and FLO resistance in P. multocida were significantly more frequent in North America than in Europe (p[≤]0.05). TUL resistance increased significantly in P. multocida after 2013 (p=0.038), with similar non significant trends in M. haemolytica and H. somni. FLO resistance decreased significantly in H. somni after 2013 (p=0.013). Egger's test identified significant funnel plot asymmetry for ENR resistance in H. somni and PEN resistance in M. haemolytica, suggesting possible small study effects. Conclusion: These results offer insights into distribution of phenotypic resistance across pathogens and regions, informing BRD antimicrobial treatment guidelines and One-Health antimicrobial stewardship aimed at preserving the effectiveness of medically important antimicrobials.
ER -